No Data
No Data
Orient Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Orient Pharmaceutical Co., Ltd.
Aurisco Pharmaceutical (605116.SH): The net income for the first half of the year was 0.189 billion yuan, an increase of 96.66% compared to the same period last year.
Aurisco Pharmaceutical (605116.SH) released its semi-annual report on August 28th, 2024. In the first half of 2024, the company achieved a revenue of 0.731 billion yuan, an increase of 32.21% compared to the same period last year. The net profit attributable to shareholders of the listed company was 0.189 billion yuan, an increase of 96.66% compared to the same period last year. The company's revenue, net profit attributable to shareholders of the listed company, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses for this period have achieved significant growth compared to the same period last year. This is mainly due to: 1. The company continues to focus on its main business, with continuous promotion of advantageous active pharmaceutical ingredients and steady sales growth; 2. Formulations...
Aurisco Pharmaceutical (605116.SH): "Aurisco Convertible Bonds" will be listed for trading on the Shanghai Stock Exchange starting from August 15th.
Aurisco Pharmaceutical (605116.SH) released an announcement that its 0.812 billion yuan convertible corporate bonds will mature in 2024 and...
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Adds CN¥463m in Market Cap and Insiders Have a 76% Stake in That Gain
Aurisco Pharmaceutical (605116.SH): The active pharmaceutical ingredient for telaprevir is still in the early stage of development.
Aurisco Pharmaceutical (605116.SH) stated on the investor interaction platform on July 26 that the company's active pharmaceutical ingredient for Terlipressin is still in the early stage of development.
No Data